CORE--IMMUNOTECHNOLOGIES

$0P30FY2002DKNIH

University Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications & trials

Paper 39713332 Paper 39703542 Paper 39627458 Paper 39569450 Paper 39523344 Paper 39501168 Paper 39445781 Paper 39404771 Paper 39361354 Paper 39286616 Paper 39146793 Paper 39132170 Paper 39113097 Paper 39019846 Paper 38982571 Paper 38979297 Paper 38956443 Paper 38923876 Paper 38867260 Paper 38762883 Paper 38754417 Paper 38710716 Paper 38681976 Paper 38668926 Paper 38659935 Paper 38617292 Paper 38588766 Paper 38541774 Paper 38532542 Paper 38468710 Paper 38443061 Paper 38370739 Paper 38352404 Paper 38328082 Paper 38325549 Paper 38302662 Paper 38301482 Paper 38297106 Paper 38274832 Paper 38200309 Paper 38167707 Paper 38147796 Paper 38124090 Paper 38112776 Paper 38094249 Paper 38084400 Paper 38018975 Paper 37947218 Paper 37944574 Paper 37918482 Paper 37876206 Paper 37873351 Paper 37865088 Paper 37841854 Paper 37773691 Paper 37749267 Paper 37702381 Paper 37697042 Paper 37693528 Paper 37634026 Paper 37572875 Paper 37563299 Paper 37562653 Paper 37528116 Paper 37482173 Paper 37453563 Paper 37439560 Paper 37423717 Paper 37402431 Paper 37398925 Paper 37377217 Paper 37365285 Paper 37352927 Paper 37258747 Paper 37249599 Paper 37217495 Paper 37216241 Paper 37214858 Paper 37205426 Paper 37202423 Paper 37184392 Paper 37159340 Paper 37061110 Paper 37004219 Paper 36945480 Paper 36811878 Paper 36799898 Paper 36778265 Paper 36763596 Paper 36749911 Paper 36711911 Paper 36649428 Paper 36586772 Paper 36576985 Paper 36551771 Paper 36533926 Paper 36512731 Paper 36452260 Paper 36398862 Paper 36384110

Abstract

DESCRIPTION (Adapted from the application) This core in the previous funded period was the Immunoassay Core. The objectives of this core is to provide the investigators 1. with convenient and accurate RIA, ELISA, or Western blot analyses; 2. the opportunity to generate new antibodies or immunoassays that are not commercially available; 3. the option of rigorously evaluating the specificity of any immunoassay with a battery of supplementary biochemical analyses, including HPLC characterization and or Western blotting of antigen-containing extracts, and 4. the capability to use antigenic determinants to generate pure populations of cells for direct analysis, or for further study in conjunction with the tissue culture capabilities of the Advanced Cell Technologies (ACT) core.

View original record on NIH RePORTER →